Pfizer Inc. $PFE Shares Acquired by Aberdeen Group plc

Aberdeen Group plc grew its stake in Pfizer Inc. (NYSE:PFE) by 6.9% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 5,272,611 shares of the biopharmaceutical company’s stock after buying an additional 338,461 shares during the quarter. Aberdeen Group plc’s holdings in Pfizer were worth $128,098,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Lmcg Investments LLC lifted its holdings in shares of Pfizer by 3.8% in the 2nd quarter. Lmcg Investments LLC now owns 62,597 shares of the biopharmaceutical company’s stock valued at $1,517,000 after buying an additional 2,284 shares during the period. First Fiduciary Investment Counsel Inc. increased its stake in shares of Pfizer by 2.1% in the 2nd quarter. First Fiduciary Investment Counsel Inc. now owns 237,043 shares of the biopharmaceutical company’s stock valued at $5,746,000 after purchasing an additional 4,928 shares in the last quarter. Strengthening Families & Communities LLC increased its stake in shares of Pfizer by 871.3% in the 2nd quarter. Strengthening Families & Communities LLC now owns 2,370 shares of the biopharmaceutical company’s stock valued at $60,000 after purchasing an additional 2,126 shares in the last quarter. Blue Trust Inc. increased its stake in shares of Pfizer by 3.1% in the 2nd quarter. Blue Trust Inc. now owns 118,351 shares of the biopharmaceutical company’s stock valued at $2,869,000 after purchasing an additional 3,548 shares in the last quarter. Finally, Fourpath Capital Management LLC increased its stake in shares of Pfizer by 19.8% in the 2nd quarter. Fourpath Capital Management LLC now owns 36,855 shares of the biopharmaceutical company’s stock valued at $893,000 after purchasing an additional 6,095 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

PFE stock opened at $24.81 on Friday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The business has a 50 day simple moving average of $24.86 and a 200-day simple moving average of $24.14. The firm has a market capitalization of $141.03 billion, a PE ratio of 13.19, a price-to-earnings-growth ratio of 0.83 and a beta of 0.55. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $29.82.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business’s revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the business earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be given a $0.43 dividend. The ex-dividend date is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. Pfizer’s dividend payout ratio is 91.49%.

Analyst Ratings Changes

Several brokerages recently weighed in on PFE. UBS Group restated a “neutral” rating and issued a $28.00 price target on shares of Pfizer in a research note on Wednesday, October 1st. Bank of America lifted their price target on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Morgan Stanley cut their price objective on Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research note on Friday. Finally, Citigroup boosted their price objective on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $28.35.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.